{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:51:39Z","timestamp":1791834699845,"version":"4.3.4"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Tetraphase Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,15]]},"DOI":"10.1093\/jac\/dkab238","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T11:15:42Z","timestamp":1624446942000},"page":"2738-2739","source":"Crossref","is-referenced-by-count":7,"title":["Eravacycline pharmacokinetics in a critically ill patient receiving venovenous extracorporeal membrane oxygenation and continuous venovenous haemodialysis"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0522-505X","authenticated-orcid":false,"given":"Lauren A","family":"Igneri","sequence":"first","affiliation":[{"name":"Cooper University Health Care, One Cooper Plaza, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Green","sequence":"additional","affiliation":[{"name":"Doylestown Hospital, 595 West State Street, Doylestown, PA 18901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Dunwoody","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, 480 Arsenal St #110, Watertown, MA 02472, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars-Kristofer N","family":"Peterson","sequence":"additional","affiliation":[{"name":"Cooper University Health Care, One Cooper Plaza, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L","family":"Bartock","sequence":"additional","affiliation":[{"name":"Cooper University Health Care, One Cooper Plaza, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Puri","sequence":"additional","affiliation":[{"name":"Cooper University Health Care, One Cooper Plaza, Camden, NJ 08103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"2021091708523353700_dkab238-B1","doi-asserted-by":"crossref","first-page":"e01174-18","DOI":"10.1128\/AAC.01174-18","article-title":"Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline","volume":"62","author":"Newman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021091708523353700_dkab238-B2","year":"2020"},{"key":"2021091708523353700_dkab238-B3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40262-019-00767-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of eravacycline","volume":"58","author":"McCarthy","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2021091708523353700_dkab238-B4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13054-017-1644-y","article-title":"Medicating patients during extracorporeal membrane oxygenation: the evidence is building","volume":"21","author":"Dzierba","year":"2017","journal-title":"Crit Care"},{"key":"2021091708523353700_dkab238-B5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/jac\/dkr550","article-title":"Lack of effect of extracorporeal membrane oxygenation on tigecycline pharmacokinetics","volume":"67","author":"Veinstein","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2021091708523353700_dkab238-B6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"2021091708523353700_dkab238-B7"},{"key":"2021091708523353700_dkab238-B8"},{"key":"2021091708523353700_dkab238-B9","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/ofid\/ofx163.1359","article-title":"Pharmacokinetics (PK) of eravacycline in subjects with renal or hepatic impairment compared with healthy subjects","volume":"4 Suppl 1","author":"Horn","year":"2017","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/10\/2738\/40394403\/dkab238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/10\/2738\/40394403\/dkab238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T08:56:53Z","timestamp":1631869013000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/10\/2738\/6321602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":9,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,7,15]]},"published-print":{"date-parts":[[2021,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab238","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,7,15]]}}}